BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/9/2024 12:51:13 PM | Browse: 154 | Download: 1130
 |
Received |
|
2024-06-05 10:55 |
|
Peer-Review Started |
|
2024-06-05 10:55 |
|
First Decision by Editorial Office Director |
|
2024-06-25 10:55 |
|
Return for Revision |
|
2024-06-25 10:55 |
|
Revised |
|
2024-07-08 07:42 |
|
Publication Fee Transferred |
|
2024-07-22 12:34 |
|
Second Decision by Editor |
|
2024-07-16 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-07-16 06:00 |
|
Articles in Press |
|
2024-07-16 06:00 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-07-31 01:56 |
|
Publish the Manuscript Online |
|
2024-08-09 12:51 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ling-Xiao Xu, Jia-Jia Yuan, Ran Xue and Jun Zhou |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jun Zhou, MD, Chief Doctor, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. joelbmu@126.com |
| Key Words |
Nab-paclitaxel; Capecitabine; Biliary tract cancer; Objective response rate; Phase II clinical trial |
| Core Tip |
Our study investigates the efficacy and safety of nab-paclitaxel plus capecitabine as first-line treatment for advanced and metastatic biliary tract cancers (BTCs). Through an open-label, non-randomized, double-center, phase II clinical trial, we enrolled systemic therapy-naive patients. Our findings demonstrate that nab-paclitaxel plus capecitabine demonstrates both acceptable efficacy and safety in patients with advanced and metastatic BTCs. This regimen shows promise as a potential novel treatment option for this patient population and warrants further validation in future trials. |
| Publish Date |
2024-08-09 12:51 |
| Citation |
Xu LX, Yuan JJ, Xue R, Zhou J. Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial. World J Gastroenterol 2024; 30(30): 3564-3573 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i30/3564.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i30.3564 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
